The addition of cetuximab to platinum-based chemotherapy (cisplatin or carboplatin plus 5-
fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression …

5567 Background: Cetuximab in combination with platinum and 5FU has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

The major development of the past decade in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …

5505 Background: Cetuximab in combination with platinum and 5FU (PFEx) has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …

Abstract Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b,
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …

Objectives The aim of this study was to confirm the efficacy of the ERBITAX scheme
(paclitaxel 80 mg/m2 weekly and cetuximab 400 mg/m2 loading dose, and then 250 mg/m2 …

Background The effectiveness of the combination chemotherapy of weekly paclitaxel and
cetuximab has not yet been compared to that of the current standard regimen, EXTREME …

Background/Aim: For recurrent/metastatic squamous cell carcinoma of the head and neck
(R/M SCCHN), popular regimens containing platinum-based anticancer agents and immune …